Reported in NY times 17 hours ago.
what is concerning is the label update does not include the jcv antibody test, which was the label update Biogen applied for. the article doesn't say that, but i watched when they made their request for a label update to add the jcv antibody test. and the fda didn't add that.
instead this label update has a table of pml risk...0.3 less than 2 years, 1.5 between 2-3 then drops to 0.9 after 3 years & identifies an added pml risk of people who used a immunosuppressioves in the past.
but the fda did not add the jcv antibody test--the article did say the test had been approved in Europe by the FDA
AND i did read, in another article, the the EU & FDA are planning to begin working together by distributing approval functions in drugs used in both places---this economy is dragging all budget down i think!
the jcv antibody test is scheduled to be available to the general tysabri population-none stratisify trial people- by october in the US so i hope this label change to identify the risk of pml is just a step toward that. the EU hasn't updated their label with the jcv antibody test either, just approved the test and allowed the test to be used. The EU adding it to the label will be another step for them, they just approved the test first. the fda has done neither yet.
http://online.wsj.com/article/BT-CO-...07-712561.html
what is concerning is the label update does not include the jcv antibody test, which was the label update Biogen applied for. the article doesn't say that, but i watched when they made their request for a label update to add the jcv antibody test. and the fda didn't add that.
instead this label update has a table of pml risk...0.3 less than 2 years, 1.5 between 2-3 then drops to 0.9 after 3 years & identifies an added pml risk of people who used a immunosuppressioves in the past.
but the fda did not add the jcv antibody test--the article did say the test had been approved in Europe by the FDA
AND i did read, in another article, the the EU & FDA are planning to begin working together by distributing approval functions in drugs used in both places---this economy is dragging all budget down i think!
the jcv antibody test is scheduled to be available to the general tysabri population-none stratisify trial people- by october in the US so i hope this label change to identify the risk of pml is just a step toward that. the EU hasn't updated their label with the jcv antibody test either, just approved the test and allowed the test to be used. The EU adding it to the label will be another step for them, they just approved the test first. the fda has done neither yet.
http://online.wsj.com/article/BT-CO-...07-712561.html
Comment